



Kroger
Prescription
Plans

Adalimumab Update January 2025

Humira Market Analysis

The first wave of adalimumab biosimilars launched in July 2023. Biosimilars are FDA approved medications that are expected to produce the same clinical results as safely and effectively as the biologic medicine that the biosimilar is comparable to, referred to as the “reference product.”

KPP offers unique management for biosimilars to include engagement with medical benefit providers, collaboration at our pharmacies, and advocating for a low net-cost strategy.

Starting January 1, 2025, KPP will offer an interchangeable adalimumab biosimilar on the formulary as an additional option for members. KPP will continue to evaluate the value biosimilars can deliver as more adalimumab biosimilars continue to come to the market in an effort to drive the lowest net cost for our clients and members.

Est \$38.4 billion

*in savings through 2025 due to
adoption and use of biosimilars¹*

¹A. Mulcahy, et al. *Am J Manag Care*. July 2022.

800.917.4926

www.kpp-rx.com

Formulary Strategy Effective Jan 2025

1

Humira

Reference Product

Manufactured by AbbVie

Preferred Specialty Brand with Prior Authorization

2

Hadlima

Branded Biosimilar

Manufactured by Organon

Preferred Specialty Brand with Prior Authorization

3

Simlandi

Branded **Interchangeable** Biosimilar

Manufactured by TEVA

Preferred Specialty Brand with Prior Authorization